Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rMenB+OMV NZ vaccine lot consistency and immunogenicity in healthy infants with routine infant vaccinations
2007-007781-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease (4 arms), sponsored by Novartis. Primary endpoints: Immunogenicity after 3 doses, Lot-to-lot consistency and 1 more. Started Mar 2008; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2007-007781-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007781-38.